Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK MHRA's (Medicines and Healthcare products Regulatory Authority) DES (Device Evaluation Service) updates radiology reviews

This article was originally published in Clinica

Executive Summary

The Device Evaluation Service (DES) of the UK's Medicines and Healthcare products Regulatory Authority (MHRA) has published the third edition of Comparative specifications of single plane cardiovascular imaging systems. It covers the General Electric Innova 2000, Philips Integris Allura Xper FD10, MIS Shimadzu Angiospeed HF, Siemens Axiom Artis dFC, and Toshiba's Infinix CCi and Cci-FPD, among others. The DES' comparative specifications reports aim to assist prospective purchasers in the selection of equipment appropriate to their requirements, but do not contain evaluation data; the DES can supply the related evaluation reports upon request ([email protected]). As part of its ongoing programme of evaluations of direct digital radiography systems, the DES has published a Digital imaging systems for general radiography report on the General Electric Medical Systems Revolution XR/d2.

You may also be interested in...



US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT054231

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel